2016
DOI: 10.1080/14787210.2017.1268530
|View full text |Cite
|
Sign up to set email alerts
|

Future therapies targeted towards eliminatingCandidabiofilms and associated infections

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

1
15
0

Year Published

2017
2017
2021
2021

Publication Types

Select...
8
2

Relationship

0
10

Authors

Journals

citations
Cited by 25 publications
(16 citation statements)
references
References 247 publications
(83 reference statements)
1
15
0
Order By: Relevance
“…Interestingly, we observed that E. coli and S. enterica growing rate was superior after the toothbrush immersion in Listerine. The only exception was observed against C. albicans, wich had a lower growing rate after the immersion; this last result is similar to the observations reported in 2016 in a literature review that referred to Listerine as a superior chemical agent along with CHX in Candida biofilm elimination [19].…”
Section: Discussionsupporting
confidence: 89%
“…Interestingly, we observed that E. coli and S. enterica growing rate was superior after the toothbrush immersion in Listerine. The only exception was observed against C. albicans, wich had a lower growing rate after the immersion; this last result is similar to the observations reported in 2016 in a literature review that referred to Listerine as a superior chemical agent along with CHX in Candida biofilm elimination [19].…”
Section: Discussionsupporting
confidence: 89%
“…In the last years, novel vaginal drug delivery formulations have focused attention to treat fungal infections. Candida species are the fourth leading agent of health care associated infections worldwide with the highest mortality rate of all nosocomial bloodstream infections, even exceeding those caused by Staphylococcus aureus and Pseudomonas aeruginosa (Bandara, Matsubara, & Samaranayake, 2017).…”
Section: Introductionmentioning
confidence: 99%
“…Furthermore, in vivo intervention studies with L. reuteri (DSM 17938 and ATCC PTA 5289) administered in food or as lozenges reduced Candida presence and load (Hatakka et al, 2007;Kraft-Bodi et al, 2015), increased unstimulated whole saliva in the elderly (Hatakka et al, 2007), and reduced the gingival index in various patient groups (Krasse et al, 2006;Schlagenhauf et al, 2016;Vivekananda, Vandana, & Bhat, 2010). Two recent papers review the potential of probiotic therapy as anti-Candida therapy and as non-conventional treatment of OLP (Bandara, Matsubara, & Samaranayake, 2017;Han, Zhang, Tan, & Zhou, 2017). In line with this, it was our aim to investigate whether L. reuteri (DSM 17938 and ATCC PTA 5289) could reduce the recurrence of OC in patients with OLP and even the need of symptomatic treatment of OLP-related symptoms.…”
Section: Introductionmentioning
confidence: 99%